[Global approach to the treatment of chronic asthma in adults].
The reduction of the bronchial inflammatory reaction, in itself a triggering event for bronchospasm, is one of the main targets for treatment in bronchial asthma. An early engagement of anti-inflammatory agents is, therefore, as necessary for long-term treatment as the reduction of irritating or antigenic environmental factors. Assessment of therapeutic efficacy necessitates a regular and long-lasting surveillance of the patient. It can be provided by peak-flow measurement, performed by the patient himself. Finally, the close cooperation by patient and physician as well as the elaboration of a training program teaching the patient pathophysiology, symptoms and therapeutic possibilities are decisive for therapeutic success, i.e. the best possible restitution of pulmonary function.
Département de médecine, CHUV, Lausanne.
F
F
Spertini
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001249:Asthma / Q000503:physiopathology / Q000628:therapy*; D016535:Bronchial Hyperreactivity / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D010353:Patient Education as Topic
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents
Approche globale du traitement de l'asthme chronique de l'adulte.